Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib plus topical corticosteroids for moderate to severe atopic dermatitis in adults
2018-001726-26Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in atopic dermatitis (AD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Proportion of patients achieving IGA of 0 or 1 with a 2-point or greater improvement. Started Aug 2018; status: completed.
02
Drugs
baricitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-001726-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001726-26.